AMGEN (AMGN) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is AMGN's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Prolia and XGEVA are collapsing under biosimilar pressure, yet Amgen keeps lifting its guidance. Which newer drugs are filling the gap, and what could still derail a stock trading near a 52-week high?…

10Elms LLP reduced its position in Amgen Inc. (NASDAQ: AMGN) by 85.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 86…

Allworth Financial LP raised its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 2.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional inves…

Amgen maintains a massive global footprint and a highly diversified portfolio of medicines for serious conditions. Vertex Pharmaceuticals dominates the cystic fibrosis market and is expanding into gene editing and pain m…

Amgen Inc. (NASDAQ:AMGN) announced positive Phase 3 results showing dazodalibep significantly reduced systemic disease activity and key symptoms in patients with Sjögren's disease, a chronic autoimmune disease in which t…

Amgen's experimental Sjogren's drug meets late-stage trial goal…

Only Global Phase 3 Trial to Show Clinically Meaningful Improvements in Systemic Disease Activity and Patient-Reported Symptoms of Sjögren's Disease THOUSAND OAKS, Calif., Nov. 11, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMG…

One biotech pays retirees a bigger check today, while the other carries no net debt and is growing far faster. We put Amgen and Regeneron side by side on income, valuation, and growth to see which one earns a spot in a r…

Independent VESALIUS-CV Analysis Finds Repatha Highly Cost-Effective in High-Risk Patients Without a Prior Heart Attack or Stroke Long-Term FOURIER External-Control Analysis Shows Repatha Associated With 29% Lower Risk o…

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.…

Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the next raise, due soon, will hold up.…

Alta Advisers Ltd lifted its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 85.7% during a recent quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3…

Boston Trust Walden Corp trimmed its holdings in Amgen Inc. (NASDAQ: AMGN) by 18.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund …

Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower va…

Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart Disease Results Provide Important New Clin…

AIA Group Ltd cut its holdings in Amgen Inc. (NASDAQ: AMGN) by 25.8% in a recent quarter, according to its most recent 13F filing with the SEC. The firm owned 15,607 shares of the medical research company's stock after s…

First Nebraska Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) during a recent quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The insti…

Amgen Inc. (NASDAQ:AMGN) shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.…

THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.…

THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial ma…

Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in Ig…

THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of David W.…

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Symposium and Simultan…

THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday…

Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52 Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52 THOUSAND OAKS…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 3. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

